Orbimed Advisors Llc - Mar 25, 2024 Form 3 Insider Report for Homology Medicines, Inc. (QTTB)

Role: Director, 10%+ Owner
Signature: ORBIMED ADVISORS LLC, By: /s/ Douglas Coon, Chief Compliance Officer
Stock symbol: QTTB
Transactions as of: Mar 25, 2024
Transactions value $: $0
Form type: 3
Date filed: 3/27/2024, 05:17 PM
Previous filing: Feb 14, 2024
Next filing: Apr 3, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	QTTB	Common Stock						2.25M	Mar 25, 2024	By OrbiMed Private Investments VII, LP	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital VII LLC ("GP VII"), is the general partner of OPI VII. OrbiMed Advisors LLC ("OrbiMed Advisors"), is the managing member of GP VII. By virtue of such relationships, OrbiMed Advisors and GP VII may be deemed to have voting power and investment power over the securities held by OPI VII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VII.
F2	Each of OrbiMed Advisors and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP VII have designated a representative, Diyong Xu, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

Content

These shares are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital VII LLC ("GP VII"), is the general partner of OPI VII. OrbiMed Advisors LLC ("OrbiMed Advisors"), is the managing member of GP VII. By virtue of such relationships, OrbiMed Advisors and GP VII may be deemed to have voting power and investment power over the securities held by OPI VII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VII.

Each of OrbiMed Advisors and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP VII have designated a representative, Diyong Xu, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.